Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board  >  Bioheart, Inc.    

BIOHEART, INC.

SummaryNewsCalendarCompany 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Bioheart : Announces World's First Combination Stem Cell Treatment

share with twitter share with LinkedIn share with facebook
07/24/2014 | 09:24am EDT

SUNRISE, FL--(Marketwired - Jul 24, 2014) -  Bioheart, Inc. (OTCQB: BHRT) announced today that it has completed the world's first combination stem cell treatment with Magnum Cell Therapies (Magnum) in Honduras. A patient with congestive heart failure has been treated with a combination of AdipoCell™ or adipose derived stem cells and MyoCell® or muscle derived stem cells. AdipoCell may help to promote angiogenesis or new blood vessel formation in ischemic tissue while MyoCell may help to promote myogenesis or new muscle formation. The cells were delivered directly into the damaged areas of the heart using the MyoCath® Catheter.

The patient was treated at the Honduras Medical Center (http://www.hmc.com.hn/index.php?page=main) with Managing Director Dr. Ricardo Aguilar. The procedure was led by cardiologists Dr. Haroldo Lopez and Dr. Raul Marenco.

Kristin Comella, Bioheart's Chief Scientific Officer, attended the case and said, "We are bringing new regenerative therapies to many patients around the world. We believe that this new method of cell combination is the best therapy available to patients suffering from heart failure."

"Magnum has brought cutting edge regenerative therapies to Honduras," said Dr. Rene Fiallos, Magnum's Chief Medical Officer. "We are seeing excellent results so far with stem cell therapy and we are thrilled to expand our services."

About Bioheart, Inc.

Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

About Magnum Cell Therapies

Magnum Cell Therapies is committed to providing individualized professional service to our patients by promoting self-healing. We strive to improve our patient's health through autologous stem cell therapy and other regenerative medicine technologies. Our goal is to utilize the world's most advanced technologies and help to change the course of medicine with natural techniques. For more information on Magnum, visit www.magnumterapiacelular.com.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2013, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2014. 

© Marketwired 2014

share with twitter share with LinkedIn share with facebook
All news about BIOHEART, INC.
09/30U S STEM CELL : Confirms Date for Appeals Court Oral Arguments
PU
05/15U.S. STEM CELL, INC. : Other Events (form 8-K)
AQ
03/31U.S. STEM CELL, INC. : Other Events (form 8-K)
AQ
2019U S STEM CELL : Note 2 - going concern and management's liquidity plans
AQ
2019CORRECTED : USRM Posts Earnings for Second Quarter 2019
PR
2019US STEM CELL : USRM Posts Financial Results for First Quarter 2019
PR
2019US STEM CELL : Dr. Comella to Present at Paleo f(x) Conference in Austin, Texas
PR
2019US STEM CELL : USRM Posts Increase in Revenue and Profit Margin for 2018
PR
2019US STEM CELL : USRM Chief Science Officer Featured on One Radio Network
PR
2018US STEM CELL : USRM Hires Senior VP of US & International Sales
PR
More news
Managers
NameTitle
Miguel Tomás President, Chief Executive Officer & Director
William P. Murphy Chairman
Mark P. Borman Chief Financial Officer & Director
Sheldon T. Anderson Director
Gregory Knutson Director
Sector and Competitors
1st jan.Capitalization (M$)
BIOHEART, INC.3
GILEAD SCIENCES, INC.-6.45%76 214
REGENERON PHARMACEUTICALS54.42%61 014
VERTEX PHARMACEUTICALS-3.37%55 110
WUXI APPTEC CO., LTD.58.33%37 775
BEIGENE, LTD.80.38%27 097